To address this question, we monitored the immunohistochemical patterns of Beclin-1, LC3B and p62 followed by ultrastructural analysis in clinical settings of head and neck cancers that cover the whole histopathological spectrum of cancer development (normal, precancerous and cancerous stages) in each patient. This evidence concerns the gene MAP1LC3B and cancer.